Search

Your search keyword '"Basset-Seguin, Nicole"' showing total 466 results
Start Over Author "Basset-Seguin, Nicole"
466 results on '"Basset-Seguin, Nicole"'

2. Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach

Author

Louveau, Baptiste, primary, Nakouri, Ines, additional, Jouenne, Fanélie, additional, Baroudjian, Barouyr, additional, Sadoux, Aurélie, additional, Da Meda, Laetitia, additional, Osio, Amélie, additional, Reinhart, Fanny, additional, Robert, Julien, additional, Herms, Florian, additional, Cribier, Bernard, additional, Mortier, Laurent, additional, Jouary, Thomas, additional, Basset Seguin, Nicole, additional, Lebbé, Céleste, additional, Mourah, Samia, additional, and Battistella, Maxime, additional

Published
2024
Full Text
View/download PDF

4. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Author

Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, and Fury, Matthew G

Published
2021
Full Text
View/download PDF

7. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.

Author

Stratigos, Alexander J., Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Lewis, Karl D., Basset-Seguin, Nicole, Chang, Anne Lynn S., Dalle, Stéphane, Fernández Orland, Almudena, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R., Dummer, Reinhard, Yoo, Suk-Young, Okoye, Emmanuel, Bassukas, Ioannis, and Loquai, Carmen

Published
2024
Full Text
View/download PDF

8. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up

Author

Stratigos, Alexander J., primary, Sekulic, Aleksandar, additional, Peris, Ketty, additional, Bechter, Oliver, additional, Prey, Sorilla, additional, Lewis, Karl D., additional, Basset-Seguin, Nicole, additional, Chang, Anne Lynn S., additional, Dalle, Stéphane, additional, Fernandez Orland, Almudena, additional, Licitra, Lisa, additional, Robert, Caroline, additional, Ulrich, Claas, additional, Hauschild, Axel, additional, Migden, Michael R., additional, Dummer, Reinhard, additional, Yoo, Suk-Young, additional, Okoye, Emmanuel, additional, Bassukas, Ioannis, additional, Loquai, Carmen, additional, De Giorgi, Vincenzo, additional, Eroglu, Zeynep, additional, Gutzmer, Ralf, additional, Ulrich, Jens, additional, Puig, Susana, additional, Inocencio, Timothy J., additional, Chen, Chieh-I, additional, LaFontaine, Patrick R., additional, Seebach, Frank, additional, Lowy, Israel, additional, and Fury, Matthew G., additional

Published
2023
Full Text
View/download PDF

13. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study

Author

Gauci, Marie-Léa, Boudou, Philippe, Baroudjian, Barouyr, Vidal-Trecan, Tiphaine, Da Meda, Laetitia, Madelaine-Chambrin, Isabelle, Basset-Seguin, Nicole, Bagot, Martine, Pages, Cécile, Mourah, Samia, Resche-Rigon, Matthieu, Pinel, Sylvine, Sassier, Marion, Rouby, Franck, Eftekhari, Pirayeh, Lebbé, Céleste, and Gautier, Jean-François

Published
2018
Full Text
View/download PDF

14. Supplementary Figure from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

Author

Yurchenko, Andrey A., primary, Pop, Oltin T., primary, Ighilahriz, Meriem, primary, Padioleau, Ismael, primary, Rajabi, Fatemeh, primary, Sharpe, Hayley J., primary, Poulalhon, Nicolas, primary, Dreno, Brigitte, primary, Khammari, Amir, primary, Delord, Marc, primary, Alberti, Antonio, primary, Soufir, Nadem, primary, Battistella, Maxime, primary, Mourah, Samia, primary, Bouquet, Fanny, primary, Savina, Ariel, primary, Besse, Andrej, primary, Mendez-Lopez, Max, primary, Grange, Florent, primary, Monestier, Sandrine, primary, Mortier, Laurent, primary, Meyer, Nicolas, primary, Dutriaux, Caroline, primary, Robert, Caroline, primary, Saiag, Philippe, primary, Herms, Florian, primary, Lambert, Jerome, primary, de Sauvage, Frederic J., primary, Dumaz, Nicolas, primary, Flatz, Lukas, primary, Basset-Seguin, Nicole, primary, and Nikolaev, Sergey I., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

Author

Yurchenko, Andrey A., primary, Pop, Oltin T., primary, Ighilahriz, Meriem, primary, Padioleau, Ismael, primary, Rajabi, Fatemeh, primary, Sharpe, Hayley J., primary, Poulalhon, Nicolas, primary, Dreno, Brigitte, primary, Khammari, Amir, primary, Delord, Marc, primary, Alberti, Antonio, primary, Soufir, Nadem, primary, Battistella, Maxime, primary, Mourah, Samia, primary, Bouquet, Fanny, primary, Savina, Ariel, primary, Besse, Andrej, primary, Mendez-Lopez, Max, primary, Grange, Florent, primary, Monestier, Sandrine, primary, Mortier, Laurent, primary, Meyer, Nicolas, primary, Dutriaux, Caroline, primary, Robert, Caroline, primary, Saiag, Philippe, primary, Herms, Florian, primary, Lambert, Jerome, primary, de Sauvage, Frederic J., primary, Dumaz, Nicolas, primary, Flatz, Lukas, primary, Basset-Seguin, Nicole, primary, and Nikolaev, Sergey I., primary

Published
2023
Full Text
View/download PDF

16. Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up

Author

Stratigos, Alexander J, primary, Sekulic, Aleksandar, additional, Peris, Ketty, additional, Bechter, Oliver, additional, Prey, Sorilla, additional, Kaatz, Martin, additional, Lewis, Karl D, additional, Basset-Seguin, Nicole, additional, Chang, Anne Lynn S, additional, Dalle, Stéphane, additional, Orland, Almudena Fernandez, additional, Licitra, Lisa, additional, Robert, Caroline, additional, Ulrich, Claas, additional, Hauschild, Axel, additional, Migden, Michael R, additional, Dummer, Reinhard, additional, Yoo, Suk-Young, additional, Coates, Ebony, additional, Okoye, Emmanuel, additional, Bassukas, Ioannis, additional, Loquai, Carmen, additional, De Giorgi, Vincenzo, additional, Eroglu, Zeynep, additional, Gutzmer, Ralf, additional, Ulrich, Jens, additional, Puig, Susana, additional, Seebach, Frank, additional, Lowy, Israel, additional, and Fury, Matthew G, additional

Published
2023
Full Text
View/download PDF

17. Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Author

Hughes, Brett, primary, Grob, Jean-Jacques, additional, Bowyer, Samantha, additional, Day, Fiona, additional, Ladwa, Rahul, additional, Stein, Brian, additional, Muñoz-Couselo, Eva, additional, Basset-Seguin, Nicole, additional, Guminski, Alexander, additional, Mortier, Laurent, additional, Hauschild, Axel, additional, Migden, Michael, additional, Schmults, Chrysalyne, additional, Yoo, Suk-Young, additional, Booth, Jocelyn, additional, Seebach, Frank, additional, Lowy, Israel, additional, Fury, Matthew, additional, and Rischin, Danny, additional

Published
2023
Full Text
View/download PDF

18. Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis:The Personalizing Actinic Keratosis Treatment (PAKT) Project

Author

Morton, Colin, Baharlou, Samira, Basset-Seguin, Nicole, Calzavara-Pinton, Piergiacomo, Dirschka, Thomas, Gilaberte, Yolanda, Haedersdal, Merete, Hofbauer, Günther, Sapra, Sheetal, Waalboer-Spuij, Rick, Yip, Leona, Szeimies, Rolf Markus, Morton, Colin, Baharlou, Samira, Basset-Seguin, Nicole, Calzavara-Pinton, Piergiacomo, Dirschka, Thomas, Gilaberte, Yolanda, Haedersdal, Merete, Hofbauer, Günther, Sapra, Sheetal, Waalboer-Spuij, Rick, Yip, Leona, and Szeimies, Rolf Markus

Abstract

Actinic keratoses are pre-malignant skin lesions that require personalized care, a lack of which may result in poor treatment adherence and suboptimal outcomes. Current guidance on personalizing care is limited, nota-bly in terms of tailoring treatment to individual patient priorities and goals and supporting shared decision-making between healthcare professionals and patients. The aim of the Personalizing Actinic Keratosis Treatment panel, comprised of 12 dermatologists, was to identify current unmet needs in care and, using a modi-fied Delphi approach, develop recommendations to support personalized, long-term management of actinic ke-ratoses lesions. Panellists generated recommendations by voting on consensus statements. Voting was blinded and consensus was defined as ≥ 75% voting ’agree’ or ’strongly agree’. Statements that reached consensus were used to develop a clinical tool, of which, the goal was to improve understanding of disease chronicity, and the need for long-term, repeated treatment cy-cles. The tool highlights key decision stages across the patient journey and captures the panellist’s ratings of treatment options for attributes prioritized by patients. The expert recommendations and the clinical tool can be used to facilitate patient-centric management of ac-tinic keratoses in daily practice, encompassing patient priorities and goals to set realistic treatment expectations and improve care outcomes.

Published
2023

19. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Author

Sekulic, Aleksandar, Migden, Michael R., Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D., Miller, Chris, Mortier, Laurent, Murrell, Dedee F., Hamid, Omid, Quevedo, Jorge F., Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel, and for the ERIVANCE BCC Investigators

Published
2019
Full Text
View/download PDF

20. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Author

Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lars, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C, Forsea, Ana-Maria, Grob, Jean-Jacques, Hoeller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilios, Lebbé, Celeste, Lytvynenko, Bodhan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Van Akkooi, Alexander C J, Vieira, Ricardo, Zalaudek, Iris, Lorigan, Paul, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC), Garbe, Clau, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lar, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C, Forsea, Ana-Maria, Grob, Jean-Jacque, Hoeller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilio, Lebbé, Celeste, Lytvynenko, Bodhan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Van Akkooi, Alexander C J, Vieira, Ricardo, Zalaudek, Iri, and Lorigan, Paul

Subjects
Proto-Oncogene Proteins B-raf, Cancer Research, Consensus, Skin Neoplasms, Consensu, Systemic treatment, Oxime, HIGH-RISK MELANOMA, Antineoplastic Combined Chemotherapy Protocols, Oximes, Humans, Excisional margins, Melanoma, SENTINEL-NODE BIOPSY, Tumor thickne, Neoplasm Staging, POSTOPERATIVE STEREOTACTIC RADIOSURGERY, LENTIGO MALIGNA MELANOMA, Antineoplastic Combined Chemotherapy Protocol, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, MOHS MICROGRAPHIC SURGERY, Metastasectomy, Sentinel lymph node dissection, Interferon-alpha, RANDOMIZED PHASE-III, Adjuvant treatment, Tumor thickness, Cutaneous melanoma, Interferon-α, Mutation, Systematic Reviews as Topic, SURGICAL EXCISION MARGINS, Oncology, PRIMARY CUTANEOUS MELANOMA, STAGE IV MELANOMA, Excisional margin, Settore MED/35 - MALATTIE CUTANEE E VENEREE, DABRAFENIB PLUS TRAMETINIB, Human
Abstract

A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0mm or ≥0.8mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.

Published
2022

21. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

Author

Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lars, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C, Forsea, Ana-Maria, Grob, Jean-Jacques, Höller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilios, Lebbé, Celeste, Lytvynenko, Bohdan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Van Akkooi, Alexander C J, Vieira, Ricardo, Zalaudek, Iris, Lorigan, Paul, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Hospital Schleswig-Holstein [Kiel, Germany], Charles University [Prague] (CU), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Odense University Hospital (OUH), King‘s College London, Université libre de Bruxelles (ULB), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of L'Aquila [Italy] (UNIVAQ), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Aix Marseille Université (AMU), Medizinische Universität Wien = Medical University of Vienna, Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Aristotle University of Thessaloniki, Shupyk National Medical Academy of Postgraduate Education [Kiev] (SNMAPE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Clinic Barcelona Hospital Universitari, Hospital Universitario Virgen Macarena [Séville], Mount Vernon Cancer Centre [Northwood, UK] (MV2C), Mount Vernon Cancer Centre, University - Hospital of Modena and Reggio Emilia [Modena, Italy], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of Athens Medical School [Athens], The University of Sydney, Centro Hospitalar e Universitário [Coimbra], Università degli studi di Trieste = University of Trieste, University of Manchester [Manchester], European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC), Pecqueret, Valérie, Garbe, Clau, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lar, Bataille, Veronique, Del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C, Forsea, Ana-Maria, Grob, Jean-Jacque, Höller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilio, Lebbé, Celeste, Lytvynenko, Bohdan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Van Akkooi, Alexander C J, Vieira, Ricardo, Zalaudek, Iri, and Lorigan, Paul

Subjects
Cancer Research, Sequential digital, Consensus, Skin Neoplasms, Follow-up examinations, [SDV]Life Sciences [q-bio], Consensu, Mutation testing, NEEDLE-ASPIRATION-CYTOLOGY, Primary diagnosis, MALIGNANT-MELANOMA, AJCC classification, Positron Emission Tomography Computed Tomography, Dermatoscopy, Humans, MELANOCYTIC NEVI, Follow-up examination, Imaging diagnostic, Melanoma, SENTINEL-NODE BIOPSY, ComputingMilieux_MISCELLANEOUS, Primary diagnosi, AMERICAN JOINT COMMITTEE, Neoplasm Staging, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Confocal reflectance microscopy, Cutaneous melanoma, Imaging diagnostics, Sequential digital dermatoscopy, Total body photography, Neoplasm Recurrence, Local, [SDV] Life Sciences [q-bio], ACRAL LENTIGINOUS MELANOMA, Neoplasm Recurrence, Oncology, Local, TOTAL-BODY PHOTOGRAPHY, REFLECTANCE CONFOCAL MICROSCOPY, Settore MED/35 - MALATTIE CUTANEE E VENEREE, FOLLOW-UP, Human
Abstract

International audience; Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024.

Published
2022

23. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

Author

Basset-Seguin, Nicole, Hauschild, Axel, Grob, Jean-Jacques, Kunstfeld, Rainer, Dréno, Brigitte, Mortier, Laurent, Ascierto, Paolo A, Licitra, Lisa, Dutriaux, Caroline, Thomas, Luc, Jouary, Thomas, Meyer, Nicolas, Guillot, Bernard, Dummer, Reinhard, Fife, Kate, Ernst, D Scott, Williams, Sarah, Fittipaldo, Alberto, Xynos, Ioannis, and Hansson, Johan

Published
2015
Full Text
View/download PDF

25. Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases

Author

Moghadam, Parna, primary, Herms, Florian, additional, Baroudjian, Barouyr, additional, Tetu, Pauline, additional, Delyon, Julie, additional, Jouenne, Fanélie, additional, Boisson, Marie, additional, Louveau, Baptiste, additional, Mourah, Samia, additional, Brunet‐Possenti, Florence, additional, Duverger, Lucie, additional, Gounant, Valérie, additional, Lebbé, Céleste, additional, and Basset‐Seguin, Nicole, additional

Published
2022
Full Text
View/download PDF

26. Development of a core outcome set for basal cell carcinoma

Author

Schlessinger, Daniel I., primary, Reynolds, Kelly A., additional, Dirr, McKenzie A., additional, Ibrahim, Sarah A., additional, Yanes, Arianna F., additional, Lazaroff, Jake M., additional, Godinez-Puig, Victoria, additional, Chen, Brian R., additional, Kurta, Anastasia O., additional, Cotseones, Jill K., additional, Chiren, Sarah G., additional, Furlan, Karina C., additional, Iyengar, Sanjana, additional, Behshad, Ramona, additional, DeHoratius, Danielle M., additional, Denes, Pablo, additional, Drucker, Aaron M., additional, Dzubow, Leonard M., additional, Etzkorn, Jeremy R., additional, Harwood, Catherine A., additional, Kim, John Y.S., additional, Lawrence, Naomi, additional, Lee, Erica H., additional, Lissner, Gary S., additional, Marghoob, Ashfaq A., additional, Matin, Rubeta N., additional, Mattox, Adam R., additional, Mittal, Bharat B., additional, Thomas, J. Regan, additional, Zhou, Xiaolong Alan, additional, Zloty, David, additional, Schmitt, Jochen, additional, Kirkham, Jamie J., additional, Armstrong, April W., additional, Basset-Seguin, Nicole, additional, Billingsley, Elizabeth M., additional, Bordeaux, Jeremy S., additional, Brewer, Jerry, additional, Brown, Marc, additional, Brown, Mariah, additional, Collins, Scott A.B., additional, Fargnoli, Maria Concetta, additional, De Azevedo, Sergio Jobim, additional, Dummer, Reinhard, additional, Eggermont, Alexander, additional, Goldman, Glenn D., additional, Haedersdal, Merete, additional, Hale, Elizabeth K., additional, Hanlon, Allison, additional, Harms, Kelly L., additional, Huang, Conway C., additional, Hurst, Eva A., additional, In, Gino K., additional, Kelleners-Smeets, Nicole, additional, Kheterpal, Meenal, additional, Leshin, Barry, additional, Mcdonald, Michel, additional, Miller, Stanley J., additional, Miller, Alexander, additional, Mostow, Eliot N., additional, Trakatelli, Myrto, additional, Nehal, Kishwer S., additional, Ratner, Desiree, additional, Rogers, Howard, additional, Sarin, Kavita Y., additional, Soon, Seaver L., additional, Stasko, Thomas, additional, Storrs, Paul A., additional, Tagliaferri, Luca, additional, Vidimos, Allison T., additional, Wong, Sandra L., additional, Yu, Siegrid S., additional, Zalaudek, Iris, additional, Zeitouni, Nathalie C., additional, Zitelli, John A., additional, Poon, Emily, additional, Sobanko, Joseph F., additional, Cartee, Todd V., additional, Maher, Ian A., additional, and Alam, Murad, additional

Published
2022
Full Text
View/download PDF

29. Defining and recognising locally advanced basal cell carcinoma

Author

Amici, Jean Michel, Battistella, Maxime, Beylot-Barry, Marie, Chatellier, Anne, Dalac-Ra, Sophie, Dreno, Brigitte, Falandry, Claire, Froget, Nicolas, Giacchero, Damien, Grob, Jean Jacques, Guerreschir, Pierre, Leccia, Marie-Thérèse, Malard, Olivier, Mortier, Laurent, Routier, Emilie, Stefan, Andreea, Stefan, Dinu, Stoebner, Pierre-Emmanuel, and Basset-Seguin, Nicole

Published
2015
Full Text
View/download PDF

30. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Author

Garbe, Claus, primary, Amaral, Teresa, additional, Peris, Ketty, additional, Hauschild, Axel, additional, Arenberger, Petr, additional, Basset-Seguin, Nicole, additional, Bastholt, Lars, additional, Bataille, Veronique, additional, del Marmol, Veronique, additional, Dréno, Brigitte, additional, Fargnoli, Maria C., additional, Forsea, Ana-Maria, additional, Grob, Jean-Jacques, additional, Hoeller, Christoph, additional, Kaufmann, Roland, additional, Kelleners-Smeets, Nicole, additional, Lallas, Aimilios, additional, Lebbé, Celeste, additional, Lytvynenko, Bodhan, additional, Malvehy, Josep, additional, Moreno-Ramirez, David, additional, Nathan, Paul, additional, Pellacani, Giovanni, additional, Saiag, Philippe, additional, Stratigos, Alexander J., additional, Van Akkooi, Alexander C.J., additional, Vieira, Ricardo, additional, Zalaudek, Iris, additional, and Lorigan, Paul, additional

Published
2022
Full Text
View/download PDF

32. PARKIN Inactivation Links Parkinson’s Disease to Melanoma

Author

Hu, Hui-Han, Kannengiesser, Caroline, Lesage, Suzanne, André, Jocelyne, Mourah, Samia, Michel, Laurence, Descamps, Vincent, Basset-Seguin, Nicole, Bagot, Martine, Bensussan, Armand, Lebbé, Céleste, Deschamps, Lydia, Saiag, Philippe, Leccia, Marie-Thérèse, Bressac-de-Paillerets, Brigitte, Tsalamlal, Amel, Kumar, Rajiv, Klebe, Stephan, Grandchamp, Bernard, Andrieu-Abadie, Nathalie, Thomas, Luc, Brice, Alexis, Dumaz, Nicolas, and Soufir, Nadem

Published
2016
Full Text
View/download PDF

33. Development of a core outcome set for basal cell carcinoma

Author

Schlessinger, Daniel I., Reynolds, Kelly A., Dirr, McKenzie A., Ibrahim, Sarah A., Yanes, Arianna F., Lazaroff, Jake M., Godinez-Puig, Victoria, Chen, Brian R., Kurta, Anastasia O., Cotseones, Jill K., Chiren, Sarah G., Furlan, Karina C., Iyengar, Sanjana, Behshad, Ramona, DeHoratius, Danielle M., Denes, Pablo, Drucker, Aaron M., Dzubow, Leonard M., Etzkorn, Jeremy R., Harwood, Catherine A., Kim, John Y.S., Lawrence, Naomi, Lee, Erica H., Lissner, Gary S., Marghoob, Ashfaq A., Matin, Rubeta N., Mattox, Adam R., Mittal, Bharat B., Thomas, J. Regan, Zhou, Xiaolong Alan, Zloty, David, Schmitt, Jochen, Kirkham, Jamie J., Armstrong, April W., Basset-Seguin, Nicole, Billingsley, Elizabeth M., Bordeaux, Jeremy S., Brewer, Jerry, Brown, Marc, Brown, Mariah, Collins, Scott A.B., Fargnoli, Maria Concetta, De Azevedo, Sergio Jobim, Dummer, Reinhard, Eggermont, Alexander, Goldman, Glenn D., Haedersdal, Merete, Hale, Elizabeth K., Hanlon, Allison, Harms, Kelly L., Huang, Conway C., Hurst, Eva A., In, Gino K., Kelleners-Smeets, Nicole, Kheterpal, Meenal, Leshin, Barry, Mcdonald, Michel, Miller, Stanley J., Miller, Alexander, Mostow, Eliot N., Trakatelli, Myrto, Nehal, Kishwer S., Ratner, Desiree, Rogers, Howard, Sarin, Kavita Y., Soon, Seaver L., Stasko, Thomas, Storrs, Paul A., Tagliaferri, Luca, Vidimos, Allison T., Wong, Sandra L., Yu, Siegrid S., Zalaudek, Iris, Zeitouni, Nathalie C., Zitelli, John A., Poon, Emily, Sobanko, Joseph F., Cartee, Todd V., Maher, Ian A., Alam, Murad, Schlessinger, Daniel I., Reynolds, Kelly A., Dirr, McKenzie A., Ibrahim, Sarah A., Yanes, Arianna F., Lazaroff, Jake M., Godinez-Puig, Victoria, Chen, Brian R., Kurta, Anastasia O., Cotseones, Jill K., Chiren, Sarah G., Furlan, Karina C., Iyengar, Sanjana, Behshad, Ramona, DeHoratius, Danielle M., Denes, Pablo, Drucker, Aaron M., Dzubow, Leonard M., Etzkorn, Jeremy R., Harwood, Catherine A., Kim, John Y.S., Lawrence, Naomi, Lee, Erica H., Lissner, Gary S., Marghoob, Ashfaq A., Matin, Rubeta N., Mattox, Adam R., Mittal, Bharat B., Thomas, J. Regan, Zhou, Xiaolong Alan, Zloty, David, Schmitt, Jochen, Kirkham, Jamie J., Armstrong, April W., Basset-Seguin, Nicole, Billingsley, Elizabeth M., Bordeaux, Jeremy S., Brewer, Jerry, Brown, Marc, Brown, Mariah, Collins, Scott A.B., Fargnoli, Maria Concetta, De Azevedo, Sergio Jobim, Dummer, Reinhard, Eggermont, Alexander, Goldman, Glenn D., Haedersdal, Merete, Hale, Elizabeth K., Hanlon, Allison, Harms, Kelly L., Huang, Conway C., Hurst, Eva A., In, Gino K., Kelleners-Smeets, Nicole, Kheterpal, Meenal, Leshin, Barry, Mcdonald, Michel, Miller, Stanley J., Miller, Alexander, Mostow, Eliot N., Trakatelli, Myrto, Nehal, Kishwer S., Ratner, Desiree, Rogers, Howard, Sarin, Kavita Y., Soon, Seaver L., Stasko, Thomas, Storrs, Paul A., Tagliaferri, Luca, Vidimos, Allison T., Wong, Sandra L., Yu, Siegrid S., Zalaudek, Iris, Zeitouni, Nathalie C., Zitelli, John A., Poon, Emily, Sobanko, Joseph F., Cartee, Todd V., Maher, Ian A., and Alam, Murad

Abstract

Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions. Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials. Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group. Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome. Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies. Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

Published
2022

39. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Author

Sekulic, Aleksandar, Migden, Michael R., Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D., Miller, Chris, Mortier, Laurent, Murrell, Dedee F., Hamid, Omid, Quevedo, Jorge F., Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel, and for the ERIVANCE BCC Investigators

Published
2017
Full Text
View/download PDF

40. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

Author

Yurchenko, Andrey A., primary, Pop, Oltin T., additional, Ighilahriz, Meriem, additional, Padioleau, Ismael, additional, Rajabi, Fatemeh, additional, Sharpe, Hayley J., additional, Poulalhon, Nicolas, additional, Dreno, Brigitte, additional, Khammari, Amir, additional, Delord, Marc, additional, Alberti, Antonio, additional, Soufir, Nadem, additional, Battistella, Maxime, additional, Mourah, Samia, additional, Bouquet, Fanny, additional, Savina, Ariel, additional, Besse, Andrej, additional, Mendez-Lopez, Max, additional, Grange, Florent, additional, Monestier, Sandrine, additional, Mortier, Laurent, additional, Meyer, Nicolas, additional, Dutriaux, Caroline, additional, Robert, Caroline, additional, Saiag, Philippe, additional, Herms, Florian, additional, Lambert, Jerome, additional, de Sauvage, Frederic J., additional, Dumaz, Nicolas, additional, Flatz, Lukas, additional, Basset-Seguin, Nicole, additional, and Nikolaev, Sergey I., additional

Published
2022
Full Text
View/download PDF

42. Fréquence et caractérisation des patients atteints de carcinome basocellulaire avancé dont la meilleure réponse sous inhibiteurs de la voie Hedgehog est la progression

Author

Monnet, Patricia, primary, Herms, Florian, additional, Djermane, Mourad, additional, Dalac-Rat, Sophie, additional, Dereure, Olivier, additional, Dreno, Brigitte, additional, Beylot-Barry, Marie, additional, Mortier, Laurent, additional, and Basset-Seguin, Nicole, additional

Published
2021
Full Text
View/download PDF

46. Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project.

Author

MORTON, Colin, BAHARLOU, Samira, BASSET-SEGUIN, Nicole, CALZAVARA-PINTON, Piergiacomo, DIRSCHKA, Thomas, GILABERTE, Yolanda, HAEDERSDAL, Merete, HOFBAUER, Günther, SAPRA, Sheetal, WAALBOER-SPUIJ, Rick, YIP, Leona, and SZEIMIES, Rolf-Markus

Subjects
ACTINIC keratosis, PATIENT compliance, MEDICAL personnel, KERATOSIS
Abstract

Actinic keratoses are pre-malignant skin lesions that require personalized care, a lack of which may result in poor treatment adherence and suboptimal outcomes. Current guidance on personalizing care is limited, notably in terms of tailoring treatment to individual patient priorities and goals and supporting shared decisionmaking between healthcare professionals and patients. The aim of the Personalizing Actinic Keratosis Treatment panel, comprised of 12 dermatologists, was to identify current unmet needs in care and, using a modified Delphi approach, develop recommendations to support personalized, long-term management of actinic keratoses lesions. Panellists generated recommendations by voting on consensus statements. Voting was blinded and consensus was defined as ≥75% voting ’agree’ or ’strongly agree’. Statements that reached consensus were used to develop a clinical tool, of which, the goal was to improve understanding of disease chronicity, and the need for long-term, repeated treatment cycles. The tool highlights key decision stages across the patient journey and captures the panellist’s ratings of treatment options for attributes prioritized by patients. The expert recommendations and the clinical tool can be used to facilitate patient-centric management of actinic keratoses in daily practice, encompassing patient priorities and goals to set realistic treatment expectations and improve care outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results